Active Biotech shares crater after Teva's MS drug laquinimod flops (again); FDA approves Foundation Medicine's genomic tumor diagnostic test
→ We already knew from a Phase III readout last spring that Teva’s big multiple sclerosis drug hope laquinimod didn’t work in treating …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.